---
title: 'Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in
  patients aged â‰¥ 60 years with acute myeloid leukemia refractory to standard induction
  chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase'
date: '2023-10-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37881883/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231026180915&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Not ...
disable_comments: true
---
Not ...